To investigate the role of ST3Gal5 in tumor immunogenicity, we knocked out the ST3Gal5 gene in two different murine CRC cell lines: MC38 and CT26; both of them having comparable expression of ST3Gal5 (Fig. S1A) We designed two different CRISPR/Cas9 gRNAs, targeting distinct regions in the ST3Gal5 gene. This evidence concerns the gene ST3GAL5 and colorectal carcinoma.